{
    "clinical_study": {
        "@rank": "68920", 
        "arm_group": {
            "arm_group_label": "Single arm", 
            "arm_group_type": "Other", 
            "description": "1 blood draw"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether there are persisting antibodies against\n      Japanese Encephalitis 6 years after the last vaccination with IXIARO(R) and to adapt or\n      confirm mathematical models accordingly."
        }, 
        "brief_title": "6-year Antibody Check After Third Vaccination Against Japanese Encephalitis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Other Specified Vaccination Encephalitis", 
        "condition_browse": {
            "mesh_term": [
                "Encephalitis", 
                "Encephalitis, Japanese", 
                "Encephalomyelitis, Acute Disseminated"
            ]
        }, 
        "detailed_description": {
            "textblock": "Japanese Encephalitis (JE) is a potentially devastating mosquito-borne viral disease. The JE\n      virus (JEV), a Flavivirus, is endemic to many regions in Asia, and while JE is primarily a\n      pediatric disease in the endemic regions, travelers from non-endemic regions to Asia are\n      usually na\u00efve to the virus and may be at risk for contracting JE at any age.\n\n      The present study aims to investigate antibody titers at approximately 6 years after the\n      third dose of JE vaccine (JE-VC), in a cohort of participants from an earlier booster dose\n      trial, to strengthen the statistical model of the duration of protection after the booster."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who received a booster dose of JE-VC in study IC51-311\n\n          -  Subjects who are willing to give written informed consent to participate in the trial\n\n        Exclusion Criteria:\n\n          -  Subjects who received a further dose of any Japanese Encephalitis Vaccine since study\n             IC51-311\n\n          -  Severe immunosuppression (as result of medical conditions or medication) since study\n             IC51-311, such as history of radiation therapy or cytostatic therapy\n\n          -  simultaneous participation in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039440", 
            "org_study_id": "311_FU2013", 
            "secondary_id": "2013-004366-34"
        }, 
        "intervention": {
            "arm_group_label": "Single arm", 
            "description": "One-time blood draw", 
            "intervention_name": "Blood draw", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "email": "tropenmedizin@gmail.com", 
                "last_name": "Ines Zwazl", 
                "phone": "004314016038276"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "state": "Kinderspitalgasse 15", 
                    "zip": "1090"
                }, 
                "name": "Institute for Specific Prophylaxis and Tropical Medicine"
            }, 
            "investigator": {
                "last_name": "Herwig Kollaritsch, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection", 
        "other_outcome": {
            "measure": "Projected mean duration of protection after a booster dose of JE-VC", 
            "safety_issue": "No", 
            "time_frame": "1.5 years"
        }, 
        "overall_official": {
            "affiliation": "Medizinische Universit\u00e4t Wien, Institut f\u00fcr Spezifische Prophylaxe und Tropenmedizin 1090 Wien, Kinderspitalgasse 15", 
            "last_name": "Herwig Kollaritsch, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Austria: Ethikkommission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Geometric Mean Titer (GMT) for JEV neutralizing antibodies determined by PRNT", 
            "safety_issue": "No", 
            "time_frame": "1.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039440"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Herwig Kollaritsch", 
            "investigator_title": "Ao.Univ.-Prof. Dr.med.univ.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Seroprotection Rate (SPR) defined as rate of subjects with JEV neutralizing antibody titers \u22651:10 in a PRNT", 
            "safety_issue": "No", 
            "time_frame": "1.5 years"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}